Delta Asset Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Delta Asset Management’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$987	Hold	269	–	–	﹤0.01%	570
2026 Q1	$826	Hold	269	–	–	﹤0.01%	567
2025 Q4	$1.1K	Buy	269 +48	+22%	+$238	﹤0.01%	566
2025 Q3	$1.08K	Hold	221	–	–	﹤0.01%	573
2025 Q2	$1.12K	Hold	221	–	–	﹤0.01%	562
2025 Q1	$1.17K	Hold	221	–	–	﹤0.01%	566
2024 Q4	$1.49K	Buy	221 +21	+11%	+$141	﹤0.01%	570
2024 Q3	$1.32K	Hold	200	–	–	﹤0.01%	575
2024 Q2	$1.5K	Buy	+200	New	+$1.74K	﹤0.01%	575

Other funds holding RXRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Delta Asset Management's RXRX Position: Q2 2026 in Review

Delta Asset Management held its Recursion Pharmaceuticals (RXRX) position steady in Q2 2026 at 269 shares worth $987. The position accounts for ﹤0.01% of the portfolio, ranked #570.

Delta Asset Management first reported a position in RXRX in Q2 2024 and has held it in 9 quarters since. The position peaked at $1.5K in Q2 2024. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

Delta Asset Management held 269 shares of Recursion Pharmaceuticals worth $987 as of Q2 2026.
Delta Asset Management left its Recursion Pharmaceuticals share count unchanged in Q2 2026.
Recursion Pharmaceuticals made up ﹤0.01% of Delta Asset Management's portfolio in Q2 2026, its #570 holding.
Delta Asset Management first reported a position in Recursion Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
Delta Asset Management's Recursion Pharmaceuticals position peaked at $1.5K in Q2 2024.
343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Delta Asset Management's 13F filing for Q2 2026, filed 10 Aug 2026.